** Shares of drugmaker Vericel VCEL.O fall 12.7% to $51.25 in extended trading
** VCEL expects prelim Q4 revenue in the range of about $75.2 million to $75.7 million
** Analysts estimate Q4 revenue of $77.93 mln on average -data compiled by LSEG
** VCEL expects Q4 gross margin to be ~77% vs estimates of 75.43%
** Co expects 20% to 23% total revenue growth for 2025
** As of Dec 31, 2024, co had ~$167 million in cash, restricted cash and investments, and no debt - VCEL
** Up to last close, stock gained ~53% over the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。